By Mill Chart
Last update: Oct 6, 2023
In this article we will dive into VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX) as a possible candidate for quality investing. Investors should always do their own research, but we noticed VERTEX PHARMACEUTICALS INC showing up in our Caviar Cruise quality screen, which makes it worth to investigate a bit more.
Every day, ChartMill assigns a Fundamental Rating to each stock, providing a score ranging from 0 to 10. This rating is determined by evaluating various fundamental indicators and properties.
Overall VRTX gets a fundamental rating of 6 out of 10. We evaluated VRTX against 611 industry peers in the Biotechnology industry. VRTX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. VRTX is not valued too expensively and it also shows a decent growth rate. These ratings could make VRTX a good candidate for quality investing.
Our latest full fundamental report of VRTX contains the most current fundamental analsysis.
Our Caviar Cruise screen will find you more ideas suited for quality investing.
Important Note: The content of this article is not intended as trading advice. It is essential to perform your own analysis and exercise caution when making trading decisions. The article presents observations created by automated analysis but does not guarantee any trading or investment outcomes. Always trade responsibly and make independent judgments.
VERTEX PHARMACEUTICALS INC
NASDAQ:VRTX (4/29/2024, 6:34:48 PM)
After market: 396.2 0 (0%)396.2
-1.28 (-0.32%)
These healthcare stocks can provide enviable long-term portfolio growth.
These three should have a lot of room to run.
Don't overlook these high-growth businesses.
/PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) und TreeFrog Therapeutics gaben heute bekannt, dass Vertex eine exklusive Lizenz für...
Good news could be just around the corner for two drugmakers not named Novo Nordisk.
/PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) y TreeFrog Therapeutics anunciaron hoy que Vertex obtuvo una licencia exclusiva para la...
Vertex is broadening its portfolio.
Vertex is broadening its portfolio.
/PRNewswire/ -- TreeFrog Therapeutics annonce aujourd'hui que Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) a obtenu une licence exclusive de C-Stem™, la...
/PRNewswire/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to...
/CNW/ -- Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) and TreeFrog Therapeutics today announced that Vertex has obtained an exclusive license to...